The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is ...

GLP-1 agonists and dual agonists can cause hypoglycemia, nausea, and more. But there are ways to lessen the side effects, so you can keep taking the medication.

CHICAGO — Tariffs, the rise of GLP-1 medications and concerns about ultra-processed foods (UPFs) remain some of the major ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to know before stopping.

Experts say people who take GLP-1 weight loss medications should stay hydrated, particularly when temperatures are high. The ...

For patients with idiopathic intracranial hypertension, GLP-1 RA treatment is associated with improved clinical outcomes.

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

The new drug forces fat cells to produce more energy and doesn't impact appetite or muscle mass, unlike some existing ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...